Rocket Pharma says gene therapy gets FDA review (RCKT:NASDAQ)

Core Insights - Rocket Pharmaceuticals (NASDAQ:RCKT) saw an approximate 11% increase in premarket trading following the announcement that the FDA accepted its resubmitted marketing application for the gene therapy candidate Kresladi [4] - The FDA had previously rejected the company's biologics license application in June 2024 [4]